BCHE and Alzheimer disease: To date, there is no treatment for AD.7 Many clinical trials failed to remove Aβ in AD patients, andnone of them have reduced the pathogenesis of AD.8 Currently approved drugs can only alleviate symptoms, suchas cholinesterase inhibitors (donepezil, rivastigmine, and galantamine)that act by slowing the breakdown of acetylcholine in the synapticcleft and memantine, an antagonist of glutamatergic NMDA receptors.9,10 Despite enormous academic and commercial research investments, aneffective treatment for AD remains elusive; ergo a different researchapproach is compelling.